A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision
Morgan Stanley Compares Cempra's Solithera To Ketek, Slashes Stock's Target From $35 To $5
Can Cempra Clear Solithera Hurdle After FDA Reveal?
Intercept's Ocaliva To Experience 'Sluggish Uptake,' Investment Thesis Now 'Rapidly Shifts' To Execution In PBC
Andrew Berens Recent News
Another Wild Ride In Intercept Pharmaceuticals
Ocular Therapeutix Spikes 45% On Drug News; Morgan Stanley Upgraded Co. To Overweight
Relypsa Lost Major Ground; Feuerstein Tweets Favus Report Said 'Nothing New'
Calls Of Note: Wall Street Research Moving The Market On Thursday
Morgan Stanley: Time To Sell Rockwell Medical
Achillion Pharmaceuticals, Inc. Shares Trading At Highs Following Positive Comments From FBR Capital